Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for High-Risk Acute GVHD
NCT04139577Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation capsules in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Massachusetts General Hospital. Primary endpoint: Proportion of patients who are able to swallow >= 40 capsules at 29 Days. Started Jun 2021; status: completed.
02
Drugs
Fecal Microbiota Transplantation capsules
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04139577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139577.